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doi:10.1016/j.jmii.2010.08.010Background: Candidemia caused by non-albicans Candida spp. is of special concern because of
its high drug resistance and increase in prevalence. In clinical practice, early identification of
non-albicans candidemia is crucial. We investigated the outcome in patients with candidemia
caused by Candida albicans and Candida non-albicans.
Methods: We retrospectively evaluated candidemic patients from October 2007 to July 2009.
Underlying diseases, predisposing factors, laboratory data, and outcome were analyzed.
Results: One hundred and eight patients of candidemia were enrolled. Candida albicans and
non-albicans spp. were responsible for 56.5% (61 of 108) and 43.5% (47 of 108) of candidemia
cases, respectively. Among patients with non-albicans candidemia, significantly more
patients had neutropenia (pZ 0.001) and less patients had candiduria (pZ 0.001) and inten-
sive care unit stay (pZ 0.002) in comparison with those with C albicans candidemia. All-
cause Day 7 mortality was high in both C albicans and non-albicans spp. candidemia [44.3%
(27 of 61) vs. 29.8% (14 of 47)]. Multivariate analysis revealed that poor renal function
(odds ratio, 1.035; 95% confidence interval, 1.001e1.071; pZ 0.04) and shock (odds ratio,
19.4; 95% confidence interval, 2.53e149.5; pZ 0.004) are independent risk factors for fatal
candidemia.Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General
nter, No. 325, Section 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan.
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370 H.-W. Chi et al.Conclusions: The outcome of candidemia was poor. The identified risk factors may help us to
differentiate fatal candidemia in early infection.
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Candidemia is a serious health careerelated infection and
is associated with a poor prognosis. The incidence of can-
didemia is increasing significantly in recent years. It is the
fourth common cause of bloodstream infections (BSIs) in
U.S. hospitals and the leading cause of nosocomial BSIs in
some hospitals in Taiwan.1e4 The major risk factors for
candidemia include intravascular catheters, parenteral
hyperalimentation, and broad-spectrum antibiotics. In
terms of Candida spp., a recent shift from Candida albicans
to non-albicans has been reported.5,6 Non-albicans candi-
demia (NAC) has been shown to be responsible for 36e63%
of all candidemia cases.7e9 Furthermore, certain Candida
spp., such as Candida glabrata, have a tendency toward
decreased susceptibility to fluconazole, and others, such as
Candida krusei, are resistant to fluconazole.10,11 Several
reports have suggested that delayed initiation of antifungal
therapy for candidemia is associated with increased
mortality.12,13 NAC patients tend to be less susceptible to
fluconazole than C albicans candidemia patients.14e16
Thus, early and appropriate usage of antifungal therapy is
important for NAC. In the present study, we compared the
risk factors and prognosis of patients with C albicans can-
didemia and NAC.Methods
Patient enrollment and data collection
We retrospectively evaluated the medical and microbio-
logical data of all cases of candidemia in Tri-Service
General Hospital from October 2007 to July 2009. Demo-
graphic data, comorbidities, microbiological data, and
patients’ outcomes were evaluated. The inclusion criteria
comprised age greater than 16 years and at least one
positive blood culture yielding Candida. Patients with
candidemia caused by more than one species were
excluded. For patients with multiple candidemic episodes,
only the first episode was included.
Mycological studies
Blood cultures of present cases were performed using
BacT/ALERT Microbial Detection System (bioMe`rieux SA,
Marcy-l’Etoile, France). The isolates of the present cases
initially grew on Sabouraud dextrose agar and then identi-
fied in our laboratory by morphological (CHROMagar and
corn meal agar; Beckton, Dickinson and Company, Paris,
France) and biochemical methods (Vitek 2 YST, bioMe`rieux,
USA). Susceptibility to antifungal agents was tested by the
ATB Fungus 3 system (bioMe`rieux SA) according to themanufacturer’s instructions. Two reference strains,
Candida parasilosis ATCC 22019 and C krusei ATCC 6258,
were used as control strains for susceptibility testing. The
reference breakpoints of minimal inhibition concentrations
(MICs) were defined by Clinical and Laboratory Standards
Institute in 2008. MICs less than or equal to 4, less than or
equal to 8, less than or equal to 0.125, and less than or
equal to 1 were considered susceptible to flucytosine, flu-
conazole, itraconazole, and voriconazole, respectively.
Interpretive breakpoints for amphotericin B have not been
established by the Clinical and Laboratory Standards Insti-
tute. Clinical and Laboratory Standards Institute developed
and published an approved reference method for broth
microdilution testing of yeast.17e19 The acceptable percent
essential agreement for MICs was set at greater than or
equal to 90% for each antifungal agent against all organisms
tested.
Study variables
Clinical data, including age at the time of diagnosis,
gender, and underlying diseases, of 108 patients with can-
didemia were recorded on standardized forms. Diseases,
including alcoholism, liver cirrhosis, heart failure, renal
failure, solid organ malignancy, hematologic malignancy,
diabetes, and neutropenia, were recorded. Predisposing
factors that occurred within 30 days before the onset of
candidemia were also collected. These included central
venous catheter usage; presence of a prosthesis, implant,
or indwelling of urinary catheter; receipt of mechanical
ventilation; total parental nutrition or peripheral parental
nutrition usage; receipt of corticosteroids; blood product
transfusions; hemodialysis; gastrointestinal procedures and
operations; concomitant infections; bacteremia; total
number of antibiotics; candiduria; exposure to antifungal
agents; and intensive care unit (ICU) stay. Laboratory data
within 7 days before obtaining the first positive blood
culture were analyzed.
Definitions
Candidemia was defined as at least one positive blood
culture for Candida spp. in patients with symptoms or signs
of infection. Neutropenia was defined as an absolute
neutrophil count less than 500 cells/mL or less than
1,000 cells/mL, with a predicted nadir of less than
500 cells/mL. Presence of prosthesis/implant was defined as
Port-A or peripherally inserted central catheter implanta-
tion. Receipt of corticosteroids was defined as the usage
of a dose equivalent to at least 20 mg prednisolone per
day for more than 7 days within 4 weeks of the onset of
candidemia. Candiduria was defined as the presence of
more than 100,000 CFU/mL of Candida spp. in the urine
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Gastrointestinal procedures and operations included endo-
scopic retrograde cholangiopancreatography; use of biliary
tubes and percutaneous endoscopic gastrostomy tubes; and
other abdominal surgical procedures. All-cause Day 7
mortality was defined as death that occurred within 1 week
of the onset of candidemia. All-cause in-hospital mortality
was defined as all death that occurred during hospitalization
after the onset of candidemia. The severity of the initial
presentation of candidemia was assessed by the Acute
Physiology and Chronic Health Evaluation (APACHE) III score
after the occurrence of candidemia.
Statistical analysis
All statistical analyses were performed by using the SPSS for
windows (Version 15.0; SPSS, Chicago, IL, USA). Univariate
analysis using Pearson c2 test (for categorical measures)
and unpaired Student’s t test (for continuous measures)
were performed to demonstrate the correlation of the
possible risk factors of all-cause Day 7 mortality. A p value
less than 0.05 was considered statistically significant.
Multivariate analyses were performed to identify the
independent factors associated with all-cause Day 7
mortality by using stepwise logistic regression.Results
One hundred and eight patients of candidemia were
enrolled in our study. Candida albicans and non-albicans
spp. were responsible for 56.5% (61 of 108) and 43.5% (47 of
108) of candidemia cases, respectively. The distribution of
C non-albicans spp. was as follows: C glabrata, 17.6% (19 of
108); Candida tropicalis, 13.0% (14 of 108); C parasilosis,
11.1% (12 of 108); C krusei, 1% (1 of 108); and Candida
haemonulonii, 1% (1 of 108) (Table 1).
Among patients with NAC, significantly more patients
had neutropenia (pZ 0.001), and less patients had candi-
duria (pZ 0.001) and ICU stay (pZ 0.002) (Table 2). The
patients with receipt of mechanical ventilation (pZ 0.109)
and indwelling of urinary catheter (pZ 0.097) tend to have
more C albicans BSIs when compared with non-albicansTable 1 Distribution of Candida species and mortality rate of p
Species Candidemia
(nZ 108)
All-cause Day
(nZ
n (%) n (%) Pe
mo
of
Candida albicans 61 (56.5) 27 (65.9) 4
non-albicans Candida
species
47 (43.5) 14 (34.1) 2
Candida glabrata 19 (17.6) 6 (14.6) 3
Candida tropicalis 14 (13.0) 6 (14.6) 4
Candida parasilosis 12 (11.1) 1 (2.4)
Candida krusei 1 (1.0) 1 (2.4) 10
Candida haemulonii 1 (1.0) 0 (0)BSIs. However, these trends did not reach statistical
significance.
Susceptibility to itraconazole between patients with
C albicans BSIs and C non-albicans BSIs was statistically
different [95.1% (58 of 61) vs. 61.7% (29 of 47), p< 0.001]
(Table 3). The in vitro susceptibilities of Candida spp. to
antifungal agents are listed in Table 4.
Among patients with candidemia, all-cause Day 7
mortality rate was 38.0% (41 of 108). Day 7 mortality rates
of C albicans and NAC were demonstrated as 44.3% (27 of
61) and 29.8% (14 of 47) (Table 3). The respective all-cause
Day 7 mortality rates among NAC were as follows: C glab-
rata, 31.6% (6 of 19); C tropicalis, 42.9% (6 of 14); C par-
asilosis, 8.3% (1 of 12); C krusei, 100% (1 of 1); and Candida
haemulonii, 0% (0 of 1) (Table 1). Excluding patients with
candidemia of C krusei and C haemulonii because of the
small number of cases, patients with C albicans candidemia
had the highest rate (44.2%) of all-cause Day 7 mortality,
whereas those with C parasilosis candidemia had the lowest
mortality rate. The crude all-cause in-hospital mortality
rate was 55.6% (60 of 108). Patients with candidemia with
poor outcome have been demonstrated. Using univariate
analysis, receipt of corticosteroids (pZ 0.018); blood
product transfusion (pZ 0.003); hemodialysis (pZ 0.012);
thrombocytopenia (pZ 0.001); poor renal function (judged
by blood urea nitrogen and creatinine, p< 0.001 respec-
tively); and shock (p< 0.001) were found to be significantly
associated with all-cause Day 7 mortality (Table 5). By
multivariate analysis, only poor renal function (odds ratio,
1.035; 95% confidence interval, 1.001e1.071; pZ 0.04) and
shock (odds ratio, 19.4; 95% CI, 2.53e149.5; pZ 0.004)
were found to be independently associated with all-cause
Day 7 mortality (Table 6).
Discussion
During the 22-month period of this survey, C albicans
accounted for 56.5% of all candidemia cases in this study,
which is higher than the reports of another tertiary care
hospital in northern Taiwan (48%), lower than those of
central Taiwan (64.8%), but close to those of the United
States (55%) and Europe (58%).20e22 Even though C albicans
remains the most common species causing candidemia, theatients with candidemia
7 mortality
41)
All-cause in-hospital mortality
(nZ 60)
rcentage of
rtality in species
candidemia (%)
n (%) Percentage of
mortality in species
of candidemia (%)
4.3 36 (60.0) 59.0
9.8 24 (40.0) 51.1
1.6 12 (20.0) 63.2
2.9 9 (15.0) 64.3
8.3 2 (3.3) 16.6
0 1 (1.7) 100
0 0 (0) 0
Table 2 Demographic data of Candida albicans and non-albicans candidemia
Variables C albicans (nZ 61) C non-albicans (nZ 47) p
n (%) n (%)
Age, mean years SD (range) 70 17 (23e95) 66 15 (23e94) 0.102
Male sex 42 (68.9) 32 (68.1) 0.487
Underlying condition
Alcoholism 1 (1.6) 2 (4.3) 0.387
Liver cirrhosis 6 (9.8) 3 (6.4) 0.417
Heart failure 8 (13.1) 4 (8.5) 0.361
Renal failure 12 (19.6) 13 (27.7) 0.268
Solid organ malignancy 24 (39.3) 23 (49.9) 0.217
Hematologic malignancy 1 (1.6) 2 (4.3) 0.387
Diabetes 20 (32.8) 15 (32.0) 0.513
Neutropenia 2 (3.3) 13 (27.7) 0.001*
Predisposing factors
Central venous catheter use 35 (57.4) 22 (46.8) 0.185
Presence of prosthesis/implant 33 (54.1) 21 (44.7) 0.241
Indwelling of urinary catheter 45 (73.8) 28 (59.6) 0.097
Receipt of mechanical ventilation 37 (60.7) 22 (46.8) 0.109
TPN or PPN usage 38 (62.3) 24 (51.1) 0.163
Receipt of corticosteroids 9 (14.8) 3 (6.4) 0.160
Blood product transfusion 45 (73.8) 36 (76.6) 0.483
Hemodialysis 21 (34.4) 13 (27.7) 0.283
GI procedure and operation 15 (24.6) 8 (17.0) 0.260
Concomitant infections 57 (93.4) 44 (93.6) 0.649
Bacteremia 20 (32.8) 14 (29.8) 0.443
Total number of antibiotics, mean SD 3.76 2.57 3.64 2.85 0.624
Candiduria 38 (62.3) 13 (27.7) 0.001*
Exposure to antifungal therapy 6 (9.8) 8 (17.0) 0.180
ICU stay 43 (70.5) 19 (40.4) 0.002*
GIZ gastrointestinal; ICUZ intensive care unit; PPNZ peripheral parental nutrition; SDZ standard deviation; TPNZ total parental
nutrition.
* p value was statistically significant.
Table 3 Laboratory data, susceptibility of antifungal agents, and prognosis of candidemia (C albicans and non-albicans)
Variables C albicans (nZ 61) C non-albicans (nZ 47) p
Laboratory data, mean SD
White cell count (109/L) 12,524 7669 12,971 9672 0.792
Hemoglobin (g/L) 9.5 1.6 9.9 1.5 0.173
Platelets (109/L) 150,466 112,767 146,000 120,564 0.534
Blood urea nitrogen 56.3 41.1 45.9 43.3 0.224
Creatinine (mmol/L) 2.13 1.51 1.63 1.49 0.100
Alanine aminotransferase (U/L) 55.4 118.1 51.8 61.9 0.887
C-reactive protein (mmol/L) 15.3 10.01 13.9 10.74 0.553
Sodium 135.1 9.2 133.6 16.8 0.549
Potassium 3.66 0.77 3.64 0.88 0.907
No. of patients susceptible to antifungal agents, n (%)
Flucytosine 61 (100) 47 (100) 1.000
Fluconazole 59 (96.7) 43 (91.5) 0.236
Itraconazole 58 (95.1) 29 (61.7) <0.001*
Voriconazole 59 (96.7) 45 (95.7) 0.569
APACHE III score, mean SD 71 42.7 57.2 14.3 0.392
Outcome, n (%)
Shock 35 (57.4) 24 (51.1) 0.322
All-cause Day 7 mortality 27 (44.3) 14 (29.8) 0.079
All-cause in-hospital mortality 36 (59.0) 24 (51.1) 0.270
APACHEZ Acute Physiology and Chronic Health Evaluation; SDZ standard deviation.
* p value was statistically significant.
Table 4 In vitro susceptibility data of Candida spp.
Species Flucytosine,
MIC 4 mg/L
Fluconazole,
MIC 8 mg/L
Itraconazole,
MIC 0.125 mg/L
Voriconazole,
MIC 1 mg/L
No. susceptible (%) No. susceptible (%) No. susceptible (%) No. susceptible (%)
Candida albicans (nZ 61) 61 (100) 59 (96.7) 58 (95.1) 59 (96.7)
Candida glabrata (nZ 19) 19 (100) 19 (100) 8 (42.1) 19 (100)
Candida tropicalis (nZ 14) 14 (100) 11 (78.6) 9 (64.3) 12 (85.7)
Candida parasilosis (nZ 12) 12 (100) 11 (91.7) 11 (91.7) 12 (100)
Candida krusei (nZ 1) 0 (0) 0 (0) 0 (0) 1 (100)
Candida haemulonii (nZ 1) 1 (100) 1 (100) 1 (100) 1 (100)
MICZminimal inhibition concentrations.
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our study is 17.6% for C glabrata, 13.0% for C tropicalis,
11.1% for C parasilosis. Our results are in accordance with
the conclusions of previously published studies in two
populations: diabetic and ICU patients.9,23 Patients with
NAC are more likely to require greater dosage of flucona-
zole to cure clinically.24,25 Thus, there is a need to identify
patients at risk of NAC to initiate empirical amphotericin B
therapy or high-dose fluconazole.
In our study, we found that an increased risk of NAC was
associated with neutropenia (pZ 0.001). Other published
studies found that NAC has been associated with factors,
such as neutropenia, hematologic malignancies, allogenic
stem cell transplantation, illness severity, and prior fluco-
nazole prophylaxis.5,26e28Table 5 Univariate analysis of factors associated with all-cause
Analysis All-cause Day 7 mortal
(nZ 41)
Underlying condition, n (%)
Alcoholism 3 (7.3)
Renal failure 13 (31.7)
Hematologic malignancy 3 (7.3)
Predisposing factors, n (%)
Central venous catheter use 31 (75.6)
Receipt of corticosteroids 9 (21.9)
Blood product transfusion 37 (90.2)
Hemodialysis 18 (43.9)
ICU stay 28 (68.3)
Laboratory data, mean SD
Platelets (109/L) 108,000 92,990
Blood urea nitrogen (mg/dL) 71.0 43.4
Creatinine (mg/dL) 2.55 1.61
Patients susceptible to antifungal agents, susceptibility rate (%)
Flucytosine 41 (100)
Fluconazole 40 (97.6)
Itraconazole 33 (80.5)
Voriconazole 40 (97.6)
APACHE III score, mean SD 88.3 43.1
Outcome
Shock 38 (92.7)
APACHEZ Acute Physiology and Chronic Health Evaluation.
* p value was statistically significant.Among patients with albicans candidemia, significantly
more patients had candiduria (pZ 0.001) and ICU stay
(pZ 0.002). This phenomenon can be explained by the
spectrum in the extent of adherence to tissues, which
correlates with the pathogenicity in humans and animals.29
Candida albicans exhibits the greatest capacity to adhere
to gingival epithelial cells, followed by C tropicalis and
C glabrata.
Furthermore, there is no significant difference in the
antifungal susceptibilities between NAC and C albicans,
except to itraconazole. This may be the result of the
relatively small number of cases of C krusei in our study and
the antifungal susceptibilities among our patients with
C glabrata candidemia. Our patients with C glabrata can-
didemia have 100% susceptibility rate to fluconazole.Day 7 mortality or nonmortality in patients with candidemia
ity Nonmortality (nZ 67) p
0 (0) 0.051
11 (16.4) 0.051
0 (0) 0.051
31 (46.3) 0.088
3 (4.5) 0.018*
43 (64.2) 0.003*
15 (22.4) 0.012*
34 (50.7) 0.071
186,507 118,931 0.001*
38.9 36.4 <0.001*
1.49 1.30 <0.001*
67 (100) 1.000
62 (92.5) 0.459
55 (82.1) 0.909
64 (95.5) 0.514
55.3 26.9 0.111
21 (31.3) <0.001*
Table 6 Multivariate analysis of factors associated with all-cause Day 7 mortality or nonmortality in patients with candidemia
Variables OR 95% CI P
Lower Upper
Predisposing factors
Receipt of corticosteroids 8.551 0.741 98.631 0.09
Blood product transfusions 2.921 0.342 24.977 0.33
Hemodialysis 0.302 0.036 2.556 0.27
Laboratory data
Platelets (109/L) 1.004 0.995 1.012 0.39
Blood urea nitrogen 1.035 1.001 1.071 0.04*
Creatinine (mmol/L) 1.126 0.479 2.648 0.79
Outcome
Shock 19.465 2.535 149.462 0.004*
CIZ confidence interval; ORZ odds ratio.
* p value was statistically significant.
374 H.-W. Chi et al.However, fluconazole susceptibility and the choice of
antifungal regimen were not correlated with mortality.
Some studies also reported that patients with candidemia
were often seriously ill, and the outcome appeared to be
associated with the underlying conditions rather than with
fluconazole susceptibility or antifungal agents.30e32
All-cause Day 7 mortality was high in both patients with
C albicans and C non-albicans spp. BSIs in our study (44.3%
and 29.8%, respectively). Our findings suggest that patients
with C parasilosis candidemia have the lowest mortality
rate (8.3%); this finding is consistent with the result of prior
studies.5,33,34 Candida infections are not solely related to
the pathogenicity of the Candida spp., but also to a failure
of host-defense mechanisms and to complications associ-
ated with the patients underlying disease.35 The more
severely ill patients are at a higher risk of Candida infection
and have a worse prognosis. This is particularly evident in
ICU patients who require indwelling central venous cath-
eter and receipt of mechanical ventilation. Furthermore,
C albicans is known to be more virulent than NAC.26,36
These factors may explain the higher all-cause Day 7
mortality rate among patients with C albicans BSIs.
APACHE II score was the most common independent
predictor of candidemia-related mortality in other institu-
tions of Taiwan.22,37 In our study, higher APACHE III score at
the onset of candidemia trended toward an increased risk
of all-cause Day 7 mortality (pZ 0.111), compared with
nonmortality, but the difference did not reach statistical
significance. The overall all-cause in-hospital mortality rate
in this study was found to be 55.6%, which is compatible
with previous reports of candidemia, in which a rate of
40e76% was noted.13,30,38 Univariate analysis revealed the
receipt of corticosteroids, blood product transfusion, and
hemodialysis to be the risk factors for all-cause Day 7
mortality among candidemic patients. Administration of
glucocorticosteroids reduces chemotaxis, phagocytosis,
and phagosomal function. This may contribute to all-cause
Day 7 mortality of candidemic patients. However, poor
renal function and shock were the only two independent
factors for all-cause Day 7 mortality in the multivariate
analysis. In clinical practice, these factors could be
considered as warning signs of candidemia.In conclusion, this article defines a number of factors
with an increased risk of candidemia because of NAC
compared with C albicans candidemia. Our findings suggest
that neutropenia was associated with an increased risk and
that candiduria and ICU stay were associated with
decreased risk of BSI because of NAC. Candidemia is asso-
ciated with a poor outcome and a high mortality rate. The
independent risk factors identified in this study, such as
poor renal function and shock, may help us, in clinical
practice, to differentiate fatal candidemia from nonfatal
candidemia.Acknowledgment
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